Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Talk:CD19

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 13 years ago by Rod57 in topic Use as immunoconjugate target

Untitled

[edit]

DFAS —Preceding unsigned comment added by 128.192.23.183 (talk) 17:52, 11 August 2008 (UTC)Reply

I think something should be mentioned about the use of CD19 as a B cell neoplasm target (most recently as a target for CAR-modified T cells in CLL cf http://www.ncbi.nlm.nih.gov/pubmed/21830940 ) Ulalume (talk) 18:14, 3 November 2011 (UTC)Reply

Use as immunoconjugate target

[edit]

eg in B43-genistein, an anti-CD19 antibody linked to genistein eg for leukemia. : Chen; et al. (1999). "Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies". {{cite journal}}: Cite journal requires |journal= (help); Explicit use of et al. in: |author= (help) - Rod57 (talk) 00:03, 10 June 2013 (UTC)Reply